Investigational Drug Information for SHR6390
✉ Email this page to a colleague
What is the development status for investigational drug SHR6390?
SHR6390 is an investigational drug.
There have been 42 clinical trials for SHR6390.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 19th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Tianjin Medical University Cancer Institute and Hospital.
There are two US patents protecting this investigational drug and sixteen international patents.
Summary for SHR6390
| US Patents | 2 |
| International Patents | 16 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-07-19) |
| Vendors | 22 |
Recent Clinical Trials for SHR6390
| Title | Sponsor | Phase |
|---|---|---|
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | Hebei Medical University Fourth Hospital | Phase 2 |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer | Fudan University | Phase 2 |
Clinical Trial Summary for SHR6390
Top disease conditions for SHR6390
Top clinical trial sponsors for SHR6390
US Patents for SHR6390
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SHR6390 | ⤷ Subscribe | Pyrimidine or pyridopyridone compound and application thereof | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (Guangdong, CN) | ⤷ Subscribe |
| SHR6390 | ⤷ Subscribe | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SHR6390
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SHR6390 | Australia | AU2016333188 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | Canada | CA3000548 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | China | CN105130986 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | Denmark | DK3357922 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | European Patent Office | EP3357922 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | Spain | ES2828984 | 2035-09-30 | ⤷ Subscribe |
| SHR6390 | Hong Kong | HK1251547 | 2035-09-30 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
